Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iQ-008
- Development stage
- Preclinical
- Lead developer
- iQure Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**iQ-008** is an orally available small-molecule multitargeting compound rationally designed to address neuropathic pain and neurodegenerative diseases. It modulates **calcium channels**, **sodium ion channels**, and **TRPV1**, exhibiting significant efficacy across multiple preclinical pain models following oral dosing and demonstrating promising results in zebrafish models for neurodegeneration.[1][3][4][10][16]
Beyond the preview
Go deeper on iQ-008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iQ-008.